EQ
EquilliumDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The constructive case is that March 2026 financing materially reduced near-term solvency pressure and gives EQ504 a funded path into clinic, with management guiding to Phase 1 initiation in mid-2026 and data about six months later [#8-K-2026-03-25] [#10-K-2026-03-25].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -8.3.
What can break
Additional capital is needed sooner than expected despite runway guidance into 2029.
Momentum
88
Value
41
Sentiment
5
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $2.60 · Bear $0.80
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.56
Why
Momentum88 · Δ7d -8.3
Value41 · Δ7d +0.1
Sentiment5 · Δ7d +0.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendSoftening
Δ7d
-8.3
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
5
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-
Why this grade
Composite grade D. Momentum 88.4 / Value 41.1 / Sentiment 5.3
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$166.29M
Beta
1.87
Shares Out
63.23M
P/E (TTM) · Derived
-6.7
P/S (TTM)
21.77
P/FCF (TTM) · Derived
-8.99
Rev YoY
-100.0%
EPS YoY
-77.3%
Gross Margin
+97.1%
Op Margin
-554.9%
Net Debt
-$29.56M
Current Ratio
18.62
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology